Biogen, on the heels of a $5.6B buyout, turns its sights to early-stage assets

BioPharma Dive

In an interview, Chief Financial Officer Robin Kramer said the combined cash flow from Biogen and Apellis will not only help debt leverage ratios but also free up capacity to do other strategic deals.

M&A / DealsRead full story